M
Marc Hemmer
Researcher at Martin Luther University of Halle-Wittenberg
Publications - 8
Citations - 156
Marc Hemmer is an academic researcher from Martin Luther University of Halle-Wittenberg. The author has contributed to research in topics: Multiple drug resistance & Efflux. The author has an hindex of 6, co-authored 8 publications receiving 134 citations. Previous affiliations of Marc Hemmer include University of Luxembourg & University of Liège.
Papers
More filters
Journal ArticleDOI
6-Substituted 2-oxo-2H-1-benzopyran-3-carboxylic acid derivatives in a new approach of the treatment of cancer cell invasion and metastasis
I. Kempen,Marc Hemmer,Stéphane Counerotte,Lionel Pochet,Pascal De Tullio,Jean-Michel Foidart,Silvia Blacher,Agnès Noël,Francis Frankenne,Bernard Pirotte +9 more
TL;DR: Novel 6-substituted 2-oxo-2H-1-benzopyran-3-carboxylic acid derivatives were synthesized and their potency in reducing the invasive behaviour of HT 1080 fibrosarcoma cells was evaluated.
Journal ArticleDOI
Development of small-molecule P-gp inhibitors of the N-benzyl 1,4-dihydropyridine type: novel aspects in SAR and bioanalytical evaluation of multidrug resistance (MDR) reversal properties.
Christiane Baumert,Marianne Günthel,Sören Krawczyk,Marc Hemmer,Tom Wersig,Andreas Langner,Joséf Molnár,Hermann Lage,Andreas Hilgeroth +8 more
TL;DR: Novel series of N-benzyl 1,4-dihydropyridines prepared by facile syntheses were evaluated as multidrug resistance (MDR) modulators to restore the cytotoxic properties of varying daunorubicin applications.
Journal ArticleDOI
Discovery of novel N-phenyl 1,4-dihydropyridines with a dual mode of antimycobacterial activity.
TL;DR: The data indicate that the N-phenyl 1,4-dihydropyridines represent a novel compound class which improves the efficacy of anti-TB drugs by interfering with transmembrane efflux pumps in Mtb.
Journal ArticleDOI
The impact of the induction of multidrug resistance transporters in therapies by used drugs: recent studies.
TL;DR: The review will cover the literature of recent years and attract attention to the MDR phenomenon in cancer treatment and HIV therapy, and suggest possible strategies to overcome the problem, i.e. by using non-inducing drugs.
Journal ArticleDOI
Discovery of substituted 1,4-dihydroquinolines as novel promising class of P-glycoprotein inhibitors: First structure-activity relationships and bioanalytical studies.
TL;DR: Novel substituted 1,4-dihydroquinolines are developed as inhibitors of the transmembrane efflux pump P-glycoprotein to address questions of cellular toxicity, P-gp substrate as well as mdr reversal properties.